Contraception after gestational diabetes

Diabetes Care

Volumn 30, Issue SUPPL. 2, 2007, Pages

  Damm, Peter ^a   Mathiesen, Elisabeth R ^a   Petersen, Kresten R ^b   Kjos, Siri ^c  

^a Rigshospitalet   (Denmark)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

^c HARBOR UCLA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONTRACEPTIVE AGENT; CYPROTERONE ACETATE; ESTROGEN; ETHINYLESTRADIOL; GESTAGEN; NORETHISTERONE ACETATE; NORGESTIMATE;

ARTICLE; CONTRACEPTION; DRUG MECHANISM; HUMAN; INTRAUTERINE CONTRACEPTIVE DEVICE; PREGNANCY; PREGNANCY DIABETES MELLITUS; RISK FACTOR;

CONGENITAL ABNORMALITIES; CONTRACEPTION; CONTRACEPTIVE AGENTS, FEMALE; DIABETES MELLITUS, TYPE 2; DIABETES, GESTATIONAL; FEMALE; HUMANS; LACTATION; PREGNANCY;

EID: 34447125590     PISSN: 01495992     EISSN: 01495992     Source Type: Journal    
DOI: 10.2337/dc07-s222     Document Type: Article

References (53)

1. Lauenborg J, Hansen T, Jensen DM, Vestergaard H, Mølsted-Pedersen L, Hornnes P, Locht H, Pedersen O, Damm P: Increasing incidence of diabetes after gestational diabetes mellitus: a long-term follow-up in a Danish population. Diabetes Care 27: 1194-1199, 2004
2. Kjos SL, Peters RK, Xiang A, Henry OA, Montoro M, Buchanan TA: Predicting future diabetes in Latino women with gestational diabetes: utility of early postpartum glucose tolerance testing. Diabetes 44:586-591, 1995
3. Kim C, Newton KM, Knobb RH: Gestational diabetes and the incidence of type 2 diabetes: a systematic review. Diabetes Care 25:1862-1868, 2002
4. Ratner RE: Prevention of type 2 diabetes in women with previous gestational diabetes. Diabetes Care 30 (Suppl. 2):S242-S250, 2007
5. Clausen TD, Mathiesen E, Ekbom P, Hellmuth E, Mandrup-Poulsen T, Damm P: Poor pregnancy outcome in women with type 2 diabetes. Diabetes Care 28:323-328, 2005
6. Towner D, Kjos SL, Leung B, Montoro MM, Xiang A, Mestman JH, Buchanan TA: Congenital malformations in pregnancies complicated by NIDDM. Diabetes Care 18:1446-1451, 1995
7. Schaefer UM, Buchanan TA, Songster G, Montoro M, Xiang A, Kjos SL: Patterns of congenital anomalies and relationship to initial maternal fasting glucose levels in pregnancies complicated by type 2 and gestational diabetes. Am J Obstet Gynecol 182:313-320, 2000
8. Gabbe SG, Graves CR: Management of diabetes mellitus complicating pregnancy. Obstet Gynecol 102:857-868, 2003
9. Peters RK, Kjos SL, Xiang A, Buchanan TA: Long term diabetogenic effect of a single pregnancy in women with previous gestational diabetes mellitus. Lancet 347: 227-230, 1996
10. Verma A, Boney CM, Tucker R, Vohr BR: Insulin resistance syndrome in women with prior history of gestational diabetes mellitus. J Clin Endocrinol Metab 87:3227-3235, 2002
11. Lauenborg L, Mathiesen E, Hansen T, Glümer C, Jørgensen T, Borch-Johnsen K, Hornnes P, Pedersen O, Damm P: The prevalence of the metabolic syndrome in a Danish population of women with previous GDM is 3-fold higher than in the general population. J Clin Endocrinol Metab 90:4004-4010, 2005
12. Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M, Taskinen MR, Groop L: Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 24:683-689, 2001
13. Kjos SL, Peters RL, Xiang A, Schaefer U, Buchanan TA: Hormonal choices after gestational diabetes: subsequent pregnancy, contraception, and hormone replacement. Diabetes Care 21 (Suppl. 2): B50-B57, 1998
14. World Health Organization: Medical Eligibility Criteria for Contraceptive Use. 3rd ed. 2004. www.who.int/reproductive-health
15. Skouby SO, Molsted-Pedersen L, Kosonen A: Consequences of intrauterine contraception in diabetic women. Fertil Steril 42:568-572, 1984
16. Kimmerle R, Heinemann L, Berger M: Intrauterine devices are safe and effective contraceptives for type I diabetic women. Diabetes Care 18:1506-1507, 1995
17. Kjos S, Ballagh SA, La Cour M, Xiang A, Mishekk DR Jr: The copper T380A intrauterine device in women with type II diabetes mellitus. Obstet Gynecol 84:1006-1009, 1994
18. French RS, Cowan FM, Mansour D, Higgins JP, Robinson A, Procter T, Morris S, Guillebaud J: Levonorgetrel-releasing intrauterine systems (Mirena) compared with other methods of reversible contraceptives. Br J Obstet Gynaecol 107:1218-1225, 2001
19. Sturridge F, Guillebaud J: A risk-benefit assessment of the levonorgestrel-releasing intrauterine system. Drug Saf 15:430-440, 1996
20. Rogovskaya S, Rivera R, Grimes DA, Chen P-L, Pierre-Loius B, Prilepskaya V, Kulakov V: Effect of a levonorgestrel intrauterine system on women with type 1 diabetes: a randomised trial. Obstet Gynecol 105:811-815, 2005
21. Spellacy WN, Buhi WC, Birk SA: The effect of estrogens on carbohydrate metabolism: glucose, insulin and growth hormone studies on one hundred seventy-one women ingesting premarin, mestranol and ethinyl estradiol for six months. Am J Obstet Gynecol 114:388-392, 1971
22. Petersen KR: Pharmacodynamic effects of oral contraceptive steroids on biochemical markers for arterial thrombosis: studies in non-diabetic women and in women with insulin-dependent diabetes mellitus. Dan Med Bull 49:43-60, 2002
23. Godsland IF, Crook D, Simpson R, Proudler T, Felton C, Lees B, Anyaoku V, Devenport M, Wynn V: The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism. N Engl J Med 323:1375-1381, 1990
24. Rimm EB, Manson JE, Stampfer MJ, Colditz GA, Willett WC, Rosner B, Hennekens CH, Speizer FE: Oral contraceptive use and the risk of type 2 (non-insulin-dependent) diabetes mellitus in a large prospective study of women. Diabetologia 35: 967-972, 1992
25. Baillargeon JP, McClishe DK, Essah PA, Nestler JE: Association between current use of low-dose contraceptives and cardiovascular arterial disease: a meta-analysis. J Clin Endocrinol Metab 90:3863-3870, 2005
26. Curtis KM, Chrisman CE, Peterson HB (WHO Programme for Mapping Best Practices in Reproductive Health): Contraception for women in selected circumstances. Obstet Gynecol 99:1100-1112, 2002
27. Lidegaard Ø, Kreiner S: Contraceptives and cerebral thrombosis: a five-year national case-control study. Contraception 65:197-205, 2002
28. Lidegaard Ø, Edström B, Kreiner S: Contraceptives and venous thromboembolism: a five-year national case-control study. Contraception 65:187-196, 2002
29. Peterson KR, Skouby SO, Sidelmann J, Molsted-Pedersen L, Jespersen J: Effects of contraceptive steroids on cardiovascular risk factors in women with insulin-dependent diabetes mellitus. Am J Obstet Gynecol 171:400-405, 1994
30. Garg SK, Chase HP, Marshal G, Hoops SL, Holmes DL, Jackson WE: Oral contraceptives and renal and retinal complications in young women with insulin-dependent diabetes mellitus. JAMA 271:1099-1102, 1994
31. Klein BE, Moss SE, Klein R: Oral contraception in women with diabetes. Diabetes Care 13:8895-8898, 1990
32. Ahmed S, Hovind P, Parving H-H, Rossing P, Price DA, Laffel LM, Lansang MC, Stevanovic R, Fisher NDL, Hollenberg NK: Oral contraceptives, angiotensin-dependent renal vasoconstriction, and risk of diabetic nephropathy. Diabetes Care 28:1988-1994, 2005
33. Damm P, Mathiesen E, Clausen TD, Pedersen KR: Contraception for women with diabetes mellitus. Metabolic Syndrome and Related Disorders 3:244-249, 2005
34. Kjos SL: Optimal contraception for the diabetic woman. In Textbook of Diabetes and Pregnancy. Hod M, de Leiva A, Jovanovic L, Di Renzo, Langer O, Eds. London, Martin Dunitz, 2003, p. 589-596
35. ACOG Practice Bulletin: The use of hormonal contraception in women with coexisting medical conditions. Int J Gynecol Obstet 75:93-106, 2001
36. American Diabetes Association: Preconception care of women with diabetes (Position Statement). Diabetes Care 27 (Suppl. 1):S76-S78, 2004
37. Skouby SO, Kuhl C, Molsted-Pedersen L, Petersen K, Christensen MS: Triphasic oral contraception: Metabolic effects in normal women and those with previous gestational diabetes. Am J Obstet Gynecol 153:495-500, 1985
38. Kjos SL, Shoupe D, Douyan S, Freidman RL, Bernstein GS, Mestman JH, Mishell DR: Effect of low dose oral contraceptives on carbohydrate metabolism in women with recent gestational diabetes mellitus: results of a controlled, randomized, prospective study. Am J Obstet Gynecol 163: 1882-1827, 1990
39. Skouby SO, Andersen O, Saurbrey N, Kuhl C: Oral contraception and insulin sensitivity: in vivo assessment in normal women and women with previous gestational diabetes. J Clin Endocrinol Metab 64: 519-523, 1987
40. Kjos SL, Peters RK, Xiang A, Thomas D, Schaefer U, Buchanan TA: Contraception and the risk of type 2 diabetes mellitus in Latina women with prior gestational diabetes mellitus. JAMA 280:533-538, 1998
41. Chasan-Taber L, Willettt WC, Stampfer MJ, Hunter DJ, Colditz GA, Spiegelman D, Manson JE: A prospective study of oral contraceptives and NIDDM among U.S. women. Diabetes Care 20:330-335, 1997
42. Creasy GW, Fisher AC, Hall N, Shangold GA: Transdermal contraceptive patch delivering noregestromin and ethinyl estradiol: effects on the lipid profile. J Reprod Med 48:179-186, 2003
43. Weisberg E, Fraser IS, Lacarra M, Mishell DR Jr, Alvarez F, Brache V, Nash HA: Efficacy, bleeding patterns, and side effects of a 1-year contraceptive vaginal ring. Contraception 59:311-318, 1999
44. Seaman HE, deVries CS, Farmer RDT: The risk of venous thromboembolism in women prescribed cyproterone acetate in combination with ethinyl estradiol: a nested cohort analysis and case-control study. Hum Reprod 18:522-526, 2003
45. Wilson ES, Cruickshank J, McMaster M, Weir RJ: A prospective controlled study of the effect on blood pressure of contraceptive preparations containing different types of dosages and progestogen. Br J Obstet Gynaecol 91:1254-1260, 1984
46. Liew DF, Ng CS, Yong YM, Ratnam SS: Long term effects of Depo-Provera on carbohydrate and lipid metabolism. Contraception 31:51-64, 1985
47. Fahmy K, Abdel-Razik M, Shaaraway M, al-Kholy G, Saad S, Wagdi A, al-Azzony M: Effect of long-acting progestagen-only injectable contraceptives on carbohydrate metabolism and its hormonal profile. Contraception 44:419-430, 1991
48. Kahn HS, Curtis KM, Marchbanks PA: Effects of injectable or implantable progestin-only contraceptives on insulin-glucose metabolism and diabetes risk. Diabetes Care 26:216-225, 2003
49. Singh K, Viegas OA, Koh SC, Ratnam SS: The effect of long-term use of Norplant implants on haemostatic function. Contraception 45:141-153, 1992
50. Konje JC, Otolorin EO, Ladipo AO: The effect of continuous subdermal levonorgestrel (Norplant) on carbohydrate metabolism. Am J Obstet Gynecol 166:15-19, 1992
51. Suherman SK, Affandi B, Kovar T: The effects of Implanon on lipid metabolism in comparison with Norplant. Contraception 60:281-287, 1999
52. Kim C, Seidel KW, Begier EA, Kwok YS: Diabetes and depot medroxyprogesterone contraception in Navajo women. Arch Intern Med 161:1766-1771, 2001
53. Xiang AH, Kawakubo M, Kjos SL, Buchanan TA: Long-acting injectable progestin contraception and risk of type 2 diabetes in Latino women with prior gestational diabetes mellitus. Diabetes Care 29:613-617, 2006